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Molecular modelingModiﬁed 3D-SDAR ﬁngerprints combining 13C and 15N NMR chemical shifts augmented with inter-atomic
distances were used to model the potential of chemicals to induce phospholipidosis (PLD). A curated
dataset of 328 compounds (some of which were cationic amphiphilic drugs) was used to generate
3D-QSDAR models based on tessellations of the 3D-SDAR space with grids of different density. Composite
PLS models averaging the aggregated predictions from 100 fully randomized individual models were gen-
erated. On each of the 100 runs, the activities of an external blind test set comprised of 294 proprietary
chemicals were predicted and averaged to provide composite estimates of their PLD-inducing potentials
(PLD+ if PLD is observed, otherwise PLD). The best performing 3D-QSDAR model utilized a grid with a
density of 8 ppm  8 ppm in the C–C region, 8 ppm  20 ppm in the C–N region and 20 ppm  20 ppm in
the N–N region. The classiﬁcation predictive performance parameters of this model evaluated on the
basis of the external test set were as follows: accuracy = 0.70, sensitivity = 0.73 and speciﬁcity = 0.66. A
projection of the most frequently occurring bins on the standard coordinate space suggested a toxico-
phore composed of an aromatic ring with a centroid 3.5–7.5 Å distant from an amino-group. The presence
of a second aromatic ring separated by a 4–5 Å spacer from the ﬁrst ring and at a distance of between
5.5 Å and 7 Å from the amino-group was also associated with a PLD+ effect. These models provide com-
parable predictive performance to previously reported models for PLD with the added beneﬁt of being
based entirely on non-conﬁdential, publicly available training data and with good predictive performance
when tested in a rigorous, external validation exercise.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/3.0/).1. Introduction
Since the ﬁrst observation of phospholipidosis (PLD) by Nelson
and Fitzhugh in 1948,1 it has been noted that some drugs may
cause the appearance of microscopic foamy macrophages or cyto-
plasmic vacuoles in the cells of various tissues.2 Further investiga-
tions revealed that these bodies consist of concentric myelin-likestructures; the presence of which is considered a characteristic
sign of PLD.3 PLD is a condition caused by an excess accumulation
of phospholipids induced in several cell types by a large variety of
cationic amphiphilic drugs (CADs).4 Typical sub-structural features
present in the molecules of CADs are: (i) a hydrophobic ring
fragment and (ii) a hydrophilic amine moiety. Various possible
mechanisms resulting in the build-up of phospholipids have been
proposed: (i) inhibition of lysosomal phospholipase activity; (ii)
inhibition of lysosomal enzyme transport; (iii) enhanced phospho-
lipid biosynthesis and (iv) enhanced cholesterol biosynthesis.5
Although each of these mechanisms is plausible, later research
indicated that PLD is often species, strain (as evidenced by the var-
iation in PLD manifestation in Fischer 344 and Sprague Dawley
rats) and age, but not organ speciﬁc, thus implying a highly com-
plex PLD mechanism.6 After more than 65 years of extensive
research, PLD remains an unresolved issue due to unclear molecu-
lar causes, and its intermittent relationship with a variety of
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the accumulation of phospholipids is harmful to human health8
is still lacking, PLD’s resemblance to lysosomal storage diseases
such as Niemann-Pick type C (which may be fatal and can cause
severe toxicities9) warrants an increased attention to drugs with
potential to cause PLD.
Drug-induced phospholipidosis (DIPLD) is recognized as a
recurring preclinical ﬁnding in the drug development process.8
The process of drug development can be seriously affected by the
occurrence of PLD which can cause not only delays, but potentially
a termination of a project.10 It has been estimated that approxi-
mately 5% of the approved drugs cause DIPLD,4 which is of concern
to both pharmaceutical companies and regulators. In light of a
recent report establishing a relationship between the potential of
a compound to cause PLD and QT prolongation,11 methods to pre-
dict the potential of drug candidates to cause PLD are desirable.
An early attempt to model PLD by QSAR suggested that com-
pounds with a pKa >8 and a logP >1 for which logP2 + pKa2 >90 have
a potential to cause PLD.12 Similar models (involving more sophis-
ticated descriptors and algorithms), with somewhat broader appli-
cability have been reported by Tomizawa et al.,13 Pelletier et al.,14
Hanumegowda et al.15 and Choi et al.16 However, since all of the
above models were based on whole molecule parameters such as
the lipophilicity (logP), the ionization state (pKa) or various topo-
logical descriptors, no speciﬁc structural fragments or mechanisms
of action were pinpointed. More recent modeling attempts based
on the FDA PLWG database, which combines ﬁndings in a variety
of tissue types collected from animals (and in some cases con-
ﬁrmed by electron microscopy of human tissues collected posthu-
mously or from a biopsy) are summarized in Table 1. As a general
rule, well-balanced models for which the accuracy, the sensitivity
and the speciﬁcity are close to each-other are preferable.
Comparing the inconsistences between the reported PLD-induc-
ing potentials of seven published datasets Goracci et al.18
constructed a curated subset of the PLWG database4 containing
331 compounds.
To extend on these earlier studies, we attempted to identify
potential ‘‘toxicophores’’ in the structures of CADs using an
enhanced 3D-QSDAR (three-dimensional spectral data–activity
relationship) approach based on 13C and 15N chemical shifts and
atom-to-atom distances. Since the 3D-QSDAR description of the
molecular structure is atom speciﬁc, the identiﬁcation of particular
atoms or functional groups and their spatial arrangement associ-
ated with a PLD+ effect was a major motivation for performing this
work.Table 1
Previously published models based on the PLWG dataset
Method Compounds in
the training set
Validation
type
Accuracy
(%)
Sensitivit
(%)
MC4PC 307 10-Fold CV + ext 70.7 47.5
MC4PC 360 10-Fold CV + ext 74.6 43.6
MDL-QSAR 583* 10-Fold CV 78.8 75.7
MC4PC 583* 10-Fold CV + ext 77.6 50
MC4PC strict 435a 10-Fold CV 52.4 57.7
MC4PC relaxed 705a 10-Fold CV 58.3 59.8
MC4PC expert rules 704a 10-Fold CV 59.8 61.2
LPDM 634a 20-Fold CV 78.2 77.9
DFW 740a 10-Fold CV 52.4 69.8
MC4PC + LPDM + DFW 7141 63.2 70.3
LPDM + DFW 441b 72.8 69.8
PLS-DA 447a 70.0 69.0
Sensitivity = TP/(TP + FN); speciﬁcity = TN/(TN + FP); accuracy = (TP + TN)/(P + N); true po
* To balance the dataset some of the PLD compounds were randomly removed.
a Models for the largest reported sets.
b Model for which the accuracy  sensitivity  speciﬁcity.2. Dataset
A curated set of 331 compounds described by Goracci18 was
used to develop 3D-QSDAR models. These models were utilized
to carry out blind predictions for an external test set of 296
proprietary chemicals contained in the PLWG database. The chem-
ical names of the compounds comprising the modeling set as well
as their experimental and predicted PLD class are listed in
Table SI1. The external test set compounds are proprietary and,
respectively, their chemical names are not disclosed, as per Federal
Regulations. Chemical names will become available on request as
they become releasable when and if they enter the public domain.
Because 3D-QSDAR utilizes ﬁngerprints requiring at least 2 car-
bon atoms, chemicals with fewer carbons in their structures were
excluded. The excluded compounds were as follows: chloroform,
hydrazine and carbon tetrachloride from the modeling set (all were
PLD) and one compound from the external test set (PLD+). One
inactive chemical (PLD) from the external test set for which the
simulation of the 13C and 15N spectra failed was also excluded.
Information about the total number of PLD+ and PLD compounds
constituting the modeling and the external test sets is summarized
in Table 2.
3. Methods
3.1. Fingerprint construction
The 3D-QSDAR approach is a grid based approach, which
utilizes descriptors generated by tessellation of molecular ﬁnger-
prints constructed from NMR chemical shifts of pairs of atoms
(on the X and Y axes) and their corresponding inter-atomic dis-
tances (on the Z-axis). Depending on the density of the grid, the
ﬁngerprints’ tessellation generates large descriptor matrices often
exceeding several thousand columns, which are then processed
by PLS. Earlier versions of 3D-QSDAR relied only on 13C NMR chem-
ical shifts and carbon-to-carbon distances, which as highly sensi-
tive to their immediate chemical environment allowed
construction of accurate 3D-QSDAR models.19–21 Because the
majority of the PLD chemicals contained at least one nitrogen atom
in their structures, the original methodology relying only on 13C
chemical shifts and carbon-to-carbon distances was extended to
include 15N chemical shifts and their associated inter-atomic
distances. The following steps describe the construction of these
extended 3D-SDAR (three-dimensional spectral data–activity
relationship) ﬁngerprints.y Speciﬁcity
(%)
Compounds in
the test set
Accuracy
(%)
Sensitivity
(%)
Speciﬁcity
(%)
Refs.
81.9 61 72.7 42.9 86.7 4
88.8 381 76.8 32.4 89.7 4
78.8 4
91.9 561 64.2 59.7 68.0 4,17
46.3 17
56.4 17
58.2 17
78.6 17
76.7 17
55.2 17
76.7 17
70.0 18
sitive (TP); true negative (TN); false positive (FP); false negative (FN).
Table 2
Binary class and number of compounds in each set
Set Number of
compounds
(PLD+/PLD)
Notes
Modeling set (Goracci) 331 (127/204) Partially derived from PLWG
328 (127/201) Used for training and validation
External test set 296 (170/126) PLWG proprietary set
294 (169/125) Used as a blind external test
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nian as implemented in Hyperchem v. 8.03.22 The 13C and
15N NMR chemical shifts were simulated by ACD NMR and
XNMR predictors.23,24
(ii) The range of the 13C and 15N chemical shifts for the modeling
set was determined. In the case of d13C the covered range
was from 0 ppm to 221.5 ppm. The lower bound of the
d15N range was 367.8 ppm, while the upper bound was
442.11 ppm. Less than 1% (a total of 7) of the nitrogen atoms
in the modeling set had d >0. Because the sparse population
in the 0 ppm to 442.11 ppm region would result in descrip-
tors having a value for just a single molecule (which would
not affect the models), the positive scale of the d15N was
truncated.
(iii) To preserve the identity of the nitrogen atoms (and for sim-
plicity) their chemical shifts were translated downﬁeld by
1000 ppm which moved them past the upper bound of the
d13C region. For the purpose of structural interpretation, at
the end of the modeling process the original positions of
d15N were restored.
(iv) The through-space distances between all pairs of C–C, C–N
and N–N atoms were calculated and in conjunction with
the 13C and 15N chemical shifts were used to construct
unique ﬁngerprints representing each compound in the
3D-SDAR space. In these ﬁngerprints the chemical shift of
the ith atom dAi was placed on the X-axis, dAj on the Y-axis
and the distance between Ai and Aj on the Z-axis. One such
ﬁngerprint constructed for the structure of pyrimidine is
shown in Figure 1.
(v) The above described translation of d15N results in the forma-
tion of three distinct regions in the in the XY-plane: C–C, C–N
and N–N. Depending on the region (C–C, C–N or N–N) theFigure 1. The molecular structure of pyrimidine (a), its corresponding 13C and 15N NM
elements in (c) corresponds to the colors of the through-space distances shown in (a).
parenthesis given after the chemical shifts in (b) correspond to the atom numbers shown
XY-plane and are shown only to indicate better their location. Also in (c) the C–C, C–N a
elements for which dAi < dAj (the lighter shaded region left of the main diagonal in the X
the calculations.3D-SDAR space was tessellated into bins of different size.
Since the gyromagnetic ratio c of carbon is approximately
2.5  cN, the bins in the C–N and N–N regions were, respec-
tively, 2.5 and 6.25 times the volume of the C–C bins.
(vi) Previous PLS modeling experiments19–21 indicated inferior
performance formodels utilizing binswith a size smaller than
twice the simulation error of d13C in the C–C region. Hence, as
the d13C error in this case slightly exceeded 3.5 ppm tessella-
tions resulting in bins smaller than 8 ppm  8 ppm in the C–C
regionwere not considered. The use of larger bins whichmay
not be able to distinguishwell betweenC orN atomsplaced in
different chemical environments and thus will hamper the
structural interpretation were also avoided. Hence, in the
XY-plane all ﬁngerprints were binned using 8 ppm  8 ppm,
10 ppm  10 ppm and 12 ppm  12 ppm for the C–C region;
8 ppm  20 ppm, 10 ppm  25 ppm and 12 ppm  30 ppm
for the C–N region; and 20 ppm  20 ppm, 25 ppm  25 ppm
and 30 ppm  30 ppm for the N–N region.
(vii) For each molecule, the number of ﬁngerprint elements
belonging to a given bin (bin occupancy) was then calculated
and stored in n mmatrices (see Tables SI2–SI4), where n is
the number of compounds and m represents the number of
occupied bins. In this matrix, each bin was labeled by indices
corresponding to its coordinates in the abstract 3D-SDAR
space.
3.2. Dataset balancing
The curated Goracci dataset (the modeling set) was highly
unbalanced with a ratio between the PLD+ and PLD chemicals
in the dataset exceeding 2:3. Hence, the following strategy was
designed and implemented to correct this issue:
(i) The PLD compounds (201 in total) were split into 3 equal
groups (conditionally denoted A, B and C), each containing
67 chemicals (see Tables SI2–SI4);
(ii) Three new subsets (A + B, A + C and B + C), each containing
134 PLD chemicals were created;
(iii) The subsets from ‘‘ii’’ were combined with the 127 PLD+
chemicals to form three well-balanced sets (ABi, ACi, BCi);
each containing 261 chemicals;R spectra (b) and its resulting 3D-SDAR ﬁngerprint (c). The color of the ﬁngerprint
The 15N NMR chemical shifts are shifted downﬁeld by 1000 ppm. The numbers in
in (a). The gray circles in (c) represent the shadows of the ﬁngerprint elements in the
nd N–N regions are shown using different colors. Because dAij  dAji, the ﬁngerprint
Y-plane) contain redundant information and, respectively, are not shown or used in
Table 3
Statistical parameters for the composite PLS models using 3 LVs based on aggregated
hold-out test predictions for all 261 compounds comprising each of the ABi, ACi and
BCi sets*
Grid size 8C20N1Å 10C25N1Å 12C30N1Å
Parameter ABi ACi BCi ABi ACi BCi ABi ACi BCi
Accuracy 0.77 0.74 0.72 0.75 0.76 0.76 0.75 0.76 0.75
AUC 0.77 0.74 0.71 0.75 0.76 0.76 0.75 0.76 0.74
Sensitivity 0.69 0.68 0.60 0.69 0.71 0.71 0.67 0.69 0.66
Speciﬁcity 0.85 0.81 0.83 0.82 0.81 0.81 0.84 0.82 0.83
AUC—area under the curve.
* The individual predictions for each compound can be found in Table SI1.
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other (see Fig. 2) and the external test set of 294 chemicals
was predicted.
Information for the assignment of each individual compound to
a given subset (ABi, ACi or BCi) can be found in Tables SI1–SI4.
3.3. PLS modeling algorithm
An ensemble modeling PLS algorithm similar to bagging (boot-
strap aggregation) was utilized in order to generate composite
3D-QSDAR models. A total of 100 training (80% of the total) and
complementary hold-out test set (20% of the total) pairs were cre-
ated by a random assignment of the compounds from the modeling
set (see Fig. 2). Between 1 and 10 latent variables (LVs) were used
for modeling and the accuracy of prediction for the hold-out test
set served as a criterion to determine their optimal number. On
average, 3 LVs were found to produce models with the highest
accuracy. On each run, the predicted activities for training, hold-
out test and external test set compounds were predicted and
stored. After 100 runs, the aggregated predicted values for each
compound were averaged and a threshold of 0.5 was used to assign
each compound to one of the two activity classes (PLD+ or PLD).
Due to the employed training/hold-out test randomization proce-
dure, each compound in the composite models had two predicted
values: one, when it belonged to the training set and another,
when by chance (with a probability of 1/5) it was assigned to the
hold-out test set. Because the predicted PLD activities for the train-
ing set merely reﬂect the PLS ﬁtting ability (and hence are unre-
lated to the models’ predictive power), the results and discussion
section will be focused only on the predictions made for the
hold-out and the blind external test sets. Due to the need to bal-
ance the modeling set, a total of 9 PLS models (3 balanced sub-
sets  3 3D-QSDAR matrices of different granularity) were
developed and reported (see Table SI1). As a ﬁnal step, consensus
models combining the predictions from individual composite mod-
els based on grids of different granularity were constructed.
4. Results and discussion
4.1. Modeling performance
After the composite PLS models were built and the threshold
deﬁning the membership to a given class (PLD+ or PLD) wasFigure 2. Flowchart of the 3D-set, the classiﬁcation quality parameters for each set and grid size
were calculated (Table 3). The following notation was used to
describe the granularity of the 3D-QSDAR grid: XCYN1Å—X
ppm  X ppm for the C–C region, X ppm  Y ppm for the C–N
region, Y ppm  Y ppm for the N–N region and 1 Å resolution for
the distances between Ai and Aj. As described above, the parame-
ters reported in Table 3 are based on the aggregated predictions
for all compounds when by chance they were assigned to the hold
out-test set. Because for a given grid size, the ABi, ACi and BCi sets
overlap only partially (all PLD chemicals had only 2 composite
model predictions), no majority rule consensus models were con-
structed. Under the alternative rule, namely ‘all models agree’, 72
out of the 328 compounds comprising the modeling set were
excluded due to disagreement between the models listed in
Table 3. The predictive performance of the consensus model for
the remaining 256 compounds resulted in an accuracy of 0.83, sen-
sitivity of 0.72 and speciﬁcity of 0.90.
In contrast, the construction of majority rule consensus models
for the external test set of 294 chemicals was straightforward (see
Table 4). In this case, if the predicted class from at least two out of
three models coincided, a compound was classiﬁed as either PLD+
or PLD. From the results shown in Table 4, it can be seen that the
8C20N1Å consensus model performed best. As discussed earlier,
the granularity of the grid for this model exceeds twice the error
of d13C simulation (thus making its effect on the model’s perfor-
mance negligible), while at the same time avoiding the use of lar-
ger bins with lower information content (structurally less speciﬁc).
For comparative purposes, an ‘all models agree’ consensus
model for the external test set was also generated. However, it
led to the exclusion of an unacceptably high number of chemicalsQSDAR modeling process.
Table 4
Statistical parameters for the composite PLS models using 3 LVs based on aggregated predictions for all 294 chemicals comprising the external test set
Grid size 8C20N1Å 10C25N1Å 12C30N1Å
Parameter ABi ACi BCi Consensus ABi ACi BCi Consensus ABi ACi BCi Consensus
Accuracy 0.69 0.68 0.70 0.70 0.69 0.67 0.69 0.69 0.65 0.67 0.66 0.67
AUC 0.68 0.68 0.69 0.70 0.68 0.67 0.68 0.69 0.65 0.67 0.65 0.67
Sensitivity 0.73 0.70 0.77 0.73 0.72 0.67 0.76 0.72 0.69 0.68 0.74 0.72
Speciﬁcity 0.64 0.66 0.61 0.66 0.65 0.66 0.61 0.66 0.61 0.66 0.56 0.62
Figure 3. Examples of misclassiﬁcation: (a) activity cliffs examples; (b) conﬂicting
in vivo/cell based assay data and (c) misclassiﬁcation due to metabolism. The
misclassiﬁed compounds are indicated by a FP (false positive) or a FN (false
negative) label.
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class assignment produced by the remaining models. The classiﬁ-
cation performance parameters of this model were as follows:
accuracy = 0.75, sensitivity = 0.81 and speciﬁcity = 0.67.
4.2. Causes for misclassiﬁcation
For all ABi, ACi and BCi submodels and all grid granularities the
following compounds from the modeling set were persistently
classiﬁed as: (i) false negatives (4-cyano-5-chlorophenyl-
amidinourea, 6-hydroxydopamine, allopurinol, amantadine, amio-
darone, atropine, benzamide BZ-1, bilirubin, chlorphentermine,
clindamycin, clociguanil, cloforex, ethyl loﬂazepate ethyl ﬂucoze-
pate, levodopa, lidocaine, lysergide or lysergic acid diethylamide,
nevirapine, paraquat, pentamidine, perhexiline, phenacetin, raniti-
dine, sapropterin dihydrochloride, ursodiol and zonisamide) and
(ii) false positives (1-phenylpiperazine, amineptine, darifenacin,
doxapram, fexofenadine, ipratropium, methapyrilene, montelukast
sodium, palonosetron, physostigmine, prochlorperazine maleate,
propafenone hydrochloride, tolterodine tartrate and vinblastine).
While it is true that the inherent modeling error is the likely
cause for most of the misclassiﬁed cases, an in-depth rational anal-
ysis helped us to trace the origin of the misclassiﬁcations. Several
major contributions were identiﬁed.
4.2.1. Activity cliffs
Many chemicals were found to share a high degree of structural
similarity, but their ability to induce PLD was vastly different. Sev-
eral such cases are shown in Figure 3a. For example, the drug levo-
dopa is known to induce PLD (false negative in our modeling),
whereas its closest analogues methyldopa and carbidopa are PLD.
It is surprising that two of these drugs (levodopa and methyldopa)
differ only by the presence of a methyl group in the structure of
methyldopa. The prochlorperazine maleate and chlorpromazine
are also structurally very similar, while their ability to induce
PLD differs. Among these, the most interesting is the atropine
(PLD+)—ipratropium (PLD) pair, in which both drugs were mis-
classiﬁed by all models. However, it is also possible that at least
in some cases compounds have been labeled as PLD+ based on
evidence other than electron microscopy, and thus their experi-
mental class assignment might have been incorrect.
4.2.2. Structural peculiarity
Some of the misclassiﬁed compounds were found to differ
signiﬁcantly from the structural patterns associated with the
potential to induce PLD. For example, the bile acid ursodiol lacks
an amino-group in its structure, which is a typical feature of all
PLD+ chemicals with CADs, whereas perhexiline, amantadine and
clindamycin are all non-aromatic compounds. Bilirubin, with its
unusually bulky molecule is another such example.
4.2.3. In vivo/in vitro difference
Sun et al.25 studied a subset of 164 compounds extracted from
the PLWG database and identiﬁed 28 pairs (6 were published) for
which a cell-based PLD assay produced results opposite to those
obtained in vivo. Among these was the phenacetin (see Fig. 3b)for which the PLWG database suggested a PLD+ effect, but was
classiﬁed as PLD by our models. Because the PLD in vitro assay
does not account for metabolism and tissue speciﬁcity, its results
might be somewhat inaccurate. However, similar considerations
hold true for the PLWG database, which, due to the more conserva-
tive approach used in its creation may list a chemical as PLD+ even
if electron microscopy data is absent, but other indirect evidence is
present.
4.2.4. Metabolism
Many of the drugs in this group metabolize quickly to substan-
tially different products: 6-hydroxydopamine (forming a cysteine-
adduct metabolite), allopurinol (to uric acid), amiodarone (to
desethylamiodarone), cloforex (to chlorphentermine), lidocaine
(major metabolite 2,6-xylidine), methapyrilene (to N,N-dimethyl-
N-(pyridine-2-yl)ethane-1,2-diamine), phenacetin (to acetamino-
phen and to its toxic metabolite NAPQI, that is, detoxiﬁed by
S.H. Slavov et al. / Bioorg. Med. Chem. 22 (2014) 6706–6714 6711glutathione and results in cysteine-adduct metabolite), etc. The
effects of such biotransformation have already been reported to
affect greatly the PLD induction potential of chemicals.26 The use
of metabolites (as an external test set) instead of the parent com-
pounds (which were excluded from the modeling set), resulted in
correct predictions for the 6-hydroxydopamine and methapyrilene
(see Fig. 3c). However, the complexity of the metabolic processes
and the cascade of produced metabolites, makes the application
of metabolic pathway based QSARs a challenging endeavor.
4.2.5. Proximity to the threshold
It was also hypothesized that some compounds may have been
misclassiﬁed due to the proximity of their quantitative predicted
values to the categorization threshold of 0.5. It was found that
none of the false negative compounds was particularly close to
the threshold, with some (e.g., 4-cyano-5-chlorophenyl-amidinou-
rea, bilirubin, clociguanil and nevirapine) often having predicted
values lower than 0.2. Contrary, several false positives were very
close to it: ipratropium (0.52), propafenone hydrochloride (0.54)
and 1-phenylpiperazine (0.56).
4.3. Interpretation
An integral part of the QSAR modeling process is interpretation
of the model to identify structural features associated with the
observed biological effect. For the purpose of interpretation, the
bins with the 10 most positive PLS weights aggregated from the
100 individual models composing the consensus 8C20N1Å model
were extracted and their frequencies of occurrence were calcu-
lated. Within the 3D-QSDAR modeling paradigm, which is based
on aggregated contributions from individual models, the frequency
of occurrence is an important parameter indicating the likelihood
that a given descriptor (bin) is truly related to the modeled end-
point. In other words, if certain bins appear to be important (high
PLS weights) for the majority of the individual models (high fre-
quency of occurrence) then most likely they depict structural fea-
tures essential for the explanation of the observed effects.
Since each individual model (ABi, ACi and BCi) utilized 3 LVs, a
total of 3000 bins were extracted (10 bins  3 LVs  100 individual
models). Among the total of 9000 bins (aggregated from the ABi,
ACi and BCi models) speciﬁc to the consensus 8C20N1Å model,
150 were unique. Only 30 of these had a frequency of occurrence
higher than 1% resulting in an accumulated frequency ofFigure 4. Projections in the planes XZ (a), YZ (b) and XY (c) of the most frequently occu
(orthographic view shown in d). The color indicates the frequency of occurrence.occurrence of 81.38%. A 3D-QSDAR map indicating the position of
these bins in the 3D-SDAR space and their frequency of occurrence
is shown in Figure 4. The effect of less frequently appearing bins
associated with structural alerts other than those shown in
Figure 4, was not studied due to their weaker association with
the PLD induction potential.
A detailed examination of the 3D-SDAR map shown in Figure 4
reveals four speciﬁc clusters composed of at least three bins in close
proximity to each other: Two in the C–C region (indicated by orange
and violet contours in Fig. 4d) and two in the C–N region (indicated
by green and red contours in Fig. 4d). Interestingly, none of the bins
in the N–N region appear to contribute signiﬁcantly to any model.
This is likely an outcome of the relatively low number of chemicals
having two or more nitrogen atoms in their molecules. Respec-
tively, the frequency of occurrence of these bins will be very low
and the N–N region on the 3D-SDAR map will appear unoccupied.
The carbon-nitrogen bins contained within the red contour
depict a primary, secondary or tertiary amino-group 5–8 Å apart
from carbon atoms belonging to an aromatic ring. The bins indi-
cated by the green contour describe mostly secondary and tertiary
amino-groups connected to a ﬁrst or second order neighboring car-
bon atoms. The bins in the carbon–carbon region enveloped by the
violet contour depict the spatial relationship between carbon atoms
belonging to aromatic rings separated most often by 4–7 Å spacers.
The carbon–carbon bins contained within the orange contour
describe the location of the carbon neighbors of the amino-group
relative to the coordinates of the carbons from the aromatic rings.
At the next stage the most frequently occurring bins from
Figure 4 were projected on to the standard coordinate space to
reveal structure-speciﬁc patterns. The result for three well known
drugs, namely amoxapine, tamoxifen and chlorpromazine are
shown in Figure 5. It can be seen that multiple bins associated with
a PLD+ potential are presented in their structures. Similar to our
observation based on the 3D-SDAR map, a common structural
pattern (toxicophore) can be identiﬁed.
This common pattern is shown in Figure 6. Because the
distances between pairs of carbon atoms belonging to different
aromatic rings vary signiﬁcantly, the centroids of these rings were
used further to simplify the toxicophore. Using this simpliﬁcation,
the presence of a secondary or tertiary amino group (rarely pri-
mary) at a distance of 3.5–7.5 Å from the centroid of an aromatic
ring may serve as a structural alert (shown by solid lines in Figures
6 and 7) for identiﬁcation of compounds causing PLD. The presencerring bins having the 10 most positive PLS weights mapped on the 3D-SDAR space
Figure 5. Frequently occurring bins superimposed on the structures of amoxapine, tamoxifen and chloropromazine.
Figure 6. Proposed toxicophore associated with the PLD+ effect of chemicals.
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with a centroid 4–5 Å away from the centroid of the ﬁrst ring
(shown by dashed lines in Figures 6 and 7) may also contribute
to an increased PLD potential.
It is remarkable that the above identiﬁed hydrophilic amine
side chain and the hydrophobic ring system are the two structural
features often used to deﬁne CADs. Moreover, the structure of the
proposed toxicophore is in complete agreement with earlier ﬁnd-
ings4,16,17,27 which reported essentially identical structural alerts.
Sun et al.27 identiﬁed the presence of all 3 subunits of the currently
proposed toxicophore in the structure of promazine. However, no
further efforts to generalize the toxicophore or to determine the
most optimal distances between the subunits were reported. Using
artiﬁcial neural network models Choi et al.16 discovered similar
structural patterns, but again failed to generalize. Among the frag-
ments reported by Kruhlak et al.4 and Orogo et al.17 the structure of
our proposed toxicophore was found in 3 out of 5 and 6 out of 8
fragments, respectively. In addition, the universal nature of the
3D-SDAR ﬁngerprints does not impose ad hoc limitations regarding
the spatial conﬁguration of the fragments constituting the toxico-
phore. In contrast, earlier studies with MC4PC and LPDM17 indi-
cated that single structural alerts or features containing
fragments with more than a one-carbon separation between the
amino-group and aromatic ring could not be identiﬁed due to the
selected structural processing constraints; however, it is of note
that a combination of two smaller overlapping alerts could
indirectly achieve this.
Two groups of compounds were used to illustrate the value of
the proposed toxicophore for identiﬁcation of chemicals with a
potential to cause PLD. The ﬁrst group (Fig. 7a) consists of the three
drugs already shown in Figure 5. In these, the bins depicting the
spatial conﬁgurations between pairs of atoms (i.e., aromaticcarbons, amino-groups and their ﬁrst-order aliphatic neighbors)
were substituted by the distances between the centroids of the
associated aromatic rings and the amino-group. Although the
proximity between the phenoxy moiety and the two phenyl moie-
ties of tamoxifen falls within the above deﬁned range of 4–5 Å,
their distances to the amino-group (>9.0 Å) exceed those required
by the toxicophore. Because the ﬂexible nature of the dimethyle-
thanamine substituent allows for conformational changes that
may bring the amino group within the required optimal distance,
it is likely that the tamoxifen molecule in fact possesses a three-
center instead of the currently proposed two-center toxicophore.
Planned improvements of the 3D-QSDAR approach considering
multiple conformations (or optimization in a medium instead of
a vacuum) may help resolve such issues in the future.
The second group consists of 4 drugs (part of the proprietary
PLWG set used as an external test) whose information was released
at Drugs@FDA since the database was compiled in 2012, making
their chemical identity and PLD data no longer conﬁdential. The
publicly available experimental data suggests that these four
chemicals should be classiﬁed as PLD+ based on the presence of
keywords consistent with phospholipidosis, including alveolar his-
tiocytosis and lamellar inclusion bodies (see Table 5). As can be
seen from Figure 7b, their structures possess characteristics that
closely coincide with the geometry of the proposed toxicophore.
In the structures of lomitapide (mesylate) and bedaquiline, multi-
ple instances of two and three center toxicophores can be identi-
ﬁed. Although a two-center toxicophore was present in the
structure of lorcaserin, our best 8C20N1Å model classiﬁed it as a
PLD chemical (see Table 5). A detailed investigation28 revealed
that there is no direct evidence of a PLD+ effect caused by lorcaser-
in (with the transmission electron microscopy considered to be the
gold standard for identiﬁcation of PLD). Furthermore, in any of the
three submodels (ABi, ACi, BCi), the predicted quantitative values
for lorcaserin were very close (with an average of 0.453) to the
deﬁned threshold of 0.5, which may also explain its misclassiﬁ-
cation. In the case of alogliptin (identiﬁed as a PLD+ chemical by
two of the submodels, but not by the third) high doses at large
multiples of the human dose were required to induce PLD with
morphological changes seen only in the lungs of rats.29 However,
due to the more conservative approach used by the regulatory
bodies these two chemicals were classiﬁed as PLD+.
Although the utilized rigorous modeling strategy and the atom
speciﬁc nature of the 3D-QSDAR approach allowed the identiﬁca-
tion of structural features associated with a PLD+ potential, it has
to be emphasized that the proposed toxicophore can only reﬂect
the diversity within the training set and is limited by activity cliffs,
accuracy of PLD data, and errors due to metabolism. Therefore, its
presence would likely indicate a PLD+ chemical, while its absence
would not necessarily imply a lack of potential to induce PLD.
Figure 7. Possible 2-center (solid line) and 3-center (a combination of a solid and two dashed lines) toxicophores for the drugs part of: (a) the modeling set and (b) the
proprietary external test set information for which was recently released by FDA.
Table 5
Predictions for the four external test set drugs based on the best performing 8C20N1Å
model
Drug names Experimental class ABi ACi BCi Consensus
Alogliptin [benzoate] + + +  +
Bedaquiline + + + + +
Lomitapide [mesylate] + + + + +
Lorcaserin +    
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ity in the structural patterns11,27 between CADs causing PLD and
human ether-à-go-go-related gene (hERG) channel blockers, the
proposed toxicophore may also be useful for screening of chemi-
cals that may induce QT interval prolongation.
5. Conclusions
For the purpose of modeling the PLD potential of chemicals and
cationic amphiphilic drugs (CADs) such as anti-depressants,
antianginal, and antihistamine agents, the standard 3D-QSDAR
modeling technique was extended by adding 15N chemical shifts.
The presence of multiple bins with a high frequency of occurrence
in the C–N region of the 3D-SDAR map conﬁrmed the hypothesis
that the information contained in the chemical shifts of thenitrogen atoms and their corresponding AiAj distances to other
atoms is essential for modeling the PLD potential of chemicals.
Projection of the most frequently occurring bins on the standard
coordinate space allowed the identiﬁcation of a common structural
pattern associated with the PLD+ effect. It was composed of an
amino-group 3.5 Å and 7.5 Å away from the centroid of an aro-
matic ring. The presence of a second aromatic ring at a distance
of between 4 Å and 5 Å from the centroid of the ﬁrst one and at
a distance of between 5.5 Å and 7 Å from the amino group was also
associated with a PLD+ potential. It is hypothesized that this partic-
ular spatial arrangement plays the role of a toxicophore—that is, a
set of sub-structural units responsible for the observed PLD effect
of drugs.
The 3D-QSDAR models carried out in this work provide compa-
rable predictive performance to previously reported QSAR models
for PLD. An added beneﬁt is that they are based entirely on non-
conﬁdential, publicly available training data and demonstrate good
predictive performance when tested in a rigorous, blind external
validation exercise.
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